Date | Price Target | Rating | Analyst |
---|---|---|---|
5/28/2024 | $21.00 | Neutral | Citigroup |
4/11/2024 | $18.00 | Underperform | Bernstein |
4/3/2024 | Mkt Perform | William Blair | |
3/1/2024 | $20.00 | Neutral | Goldman |
11/17/2023 | $20.00 | Neutral | Piper Sandler |
9/11/2023 | $27.00 | Hold → Buy | Deutsche Bank |
9/7/2023 | $28.00 | Buy | Canaccord Genuity |
9/6/2023 | Hold | Argus |
Kenvue Inc. (NYSE:KVUE) ("Kenvue") today announced the Company's participation in the Barclays Global Consumer Staples Conference in Boston, Massachusetts. Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will participate in a fireside chat on Thursday, September 5, 2024, at 3:00 p.m. Eastern Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand
New Product Line Features Two Moisturizers Designed to Defend and Support the Skin's Natural Collagen SKILLMAN, N.J., Aug. 15, 2024 /PRNewswire/ -- Kenvue Inc. (NYSE:KVUE) ("Kenvue" or the "Company"), the world's largest pure-play consumer health company by revenue, is launching Neutrogena®1 Collagen Bank™ featuring the Company's patented micro-peptide technology. The launch propels Neutrogena®, the #1 Face Care Brand2, into the pre-aging category and is poised to meet the needs of Gen Z, a new generation of consumers, seeking ways to proactively prevent their skin from aging.
Net Sales of $4.0 Billion decreased 0.3%; Organic Growth1 was +1.5% Diluted EPS was $0.03; Adjusted Diluted EPS1 was $0.32 Productivity gains fuel accelerated investment in brands for future growth Reaffirms Outlook for FY24 Net Sales Growth and Adjusted Diluted EPS Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal second quarter ended June 30, 2024. "We are on track to deliver the financial targets we set for 2024, and while we are in the early days, our work to transform Kenvue into a bolder, more agile organization focused on profitable growth is producing results," said Thibaut Mongon, Chief Executive Officer. "With the progress we ha
Net Sales of $4.0 Billion decreased 0.3%; Organic Growth1 was +1.5% Diluted EPS was $0.03; Adjusted Diluted EPS1 was $0.32 Productivity gains fuel accelerated investment in brands for future growth Reaffirms Outlook for FY24 Net Sales Growth and Adjusted Diluted EPS Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal second quarter ended June 30, 2024. "We are on track to deliver the financial targets we set for 2024, and while we are in the early days, our work to transform Kenvue into a bolder, more agile organization focused on profitable growth is producing results," said Thibaut Mongon, Chief Executive Officer. "With the progress we ha
Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced a 2.5% increase in the Company's quarterly dividend as its Board of Directors declared a $0.205 per share dividend on Kenvue common stock payable in the third quarter of 2024. This is a testament to the Company's commitment to return cash to shareholders as part of its capital allocation strategy designed to enable sustainable growth and optimize total shareholder return. The third quarter dividend is payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024. About Kenvue Kenvue is the world's largest pure-play consumer health c
Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, will announce its financial results for the second quarter ending June 30, 2024, before market open on August 6, 2024. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more
10-Q - Kenvue Inc. (0001944048) (Filer)
8-K - Kenvue Inc. (0001944048) (Filer)
8-K - Kenvue Inc. (0001944048) (Filer)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
3 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa
The third quarter dividend is payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024.
Throughout the last three months, 4 analysts have evaluated Kenvue (NYSE:KVUE), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $21.0, along with a high estimate of $22.00 and a low estimate of $20.00. Observing a downward trend, the
JP Morgan analyst Andrea Teixeira maintains Kenvue (NYSE:KVUE) with a Overweight and lowers the price target from $23 to $22.
Citigroup resumed coverage of Kenvue with a rating of Neutral and set a new price target of $21.00
Bernstein initiated coverage of Kenvue with a rating of Underperform and set a new price target of $18.00
William Blair initiated coverage of Kenvue with a rating of Mkt Perform